Generic drug maker Mylan Inc. is a step closer to marketing a blockbuster treatment for multiple sclerosis after the U.S. District Court for the Southern District of New York denied a summary judgment filed by Teva Pharmaceutical Industries Ltd. , makers of Copaxone.
Canonsburg-based Mylan said the court denied the motion by Teva for a summary judgment, finding of no inequitable conduct in relation to Copaxone, Teva’s brand name drug that is used to treat multiple sclerosis. In addition, the court set a trial date of July 11 to hear Mylan’s inequitable conduct affirmative defense.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903
